Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Polycystic Ovary Syndrome 1 Oligomenorrhea 1 Motor Activity 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Leukemia, Biphenotypic, Acute 1 Leukemia 1 Insulin Resistance 1 Hyperandrogenism 1 Hodgkin Disease 1 Hirsutism 1 Fatigue 1 Diabetes Mellitus, Type 1 1 Depression 1 Congenital Abnormalities 1 Breast Neoplasms 1

Interventions

Trastuzumab 625 Paclitaxel 576 Cyclophosphamide 555 Docetaxel 484 Capecitabine 401 Letrozole 376 Fulvestrant 326 Doxorubicin 294 Carboplatin 279 Tamoxifen 275 Anastrozole 243 exemestane 228 Radiotherapy 218 Epirubicin 211 Bevacizumab 196 palbociclib 189 pertuzumab 184 Vinorelbine 167 Lapatinib 167 Gemcitabine 166 pembrolizumab 162 Surveys and Questionnaires 138 Exercise 136 Magnetic Resonance Spectroscopy 123 Fluorouracil 119 Blood Specimen Collection 118 eribulin 117 Albumin-Bound Paclitaxel 117 Drug Therapy 111 130-nm albumin-bound paclitaxel 111

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Body Composition × Clear all

NCT04638712 2023-02-09

PROTECT-03

Institut de cancérologie Strasbourg Europe

Phase NA Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡